scPharmaceuticals Inc. to Post Q2 2024 Earnings of ($0.42) Per Share, HC Wainwright Forecasts (NASDAQ:SCPH)

scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Research analysts at HC Wainwright decreased their Q2 2024 earnings estimates for shares of scPharmaceuticals in a research report issued on Wednesday, May 15th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($0.42) per share for the quarter, down from their previous forecast of ($0.35). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for scPharmaceuticals' Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.50) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at $0.65 EPS.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH traded down $0.08 during midday trading on Friday, hitting $4.75. The stock had a trading volume of 237,059 shares, compared to its average volume of 222,847. The company's 50-day moving average price is $4.89 and its 200-day moving average price is $5.39. The company has a market capitalization of $171.24 million, a P/E ratio of -3.21 and a beta of 0.09. The company has a quick ratio of 6.40, a current ratio of 6.21 and a debt-to-equity ratio of 1.60. scPharmaceuticals has a fifty-two week low of $4.01 and a fifty-two week high of $11.75.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.09. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. scPharmaceuticals had a negative return on equity of 132.39% and a negative net margin of 327.29%. During the same period in the prior year, the firm posted ($0.30) EPS.

Institutional Trading of scPharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SCPH. Perkins Capital Management Inc. acquired a new position in scPharmaceuticals during the first quarter worth about $53,000. IPG Investment Advisors LLC bought a new position in scPharmaceuticals in the 4th quarter valued at approximately $75,000. Assenagon Asset Management S.A. bought a new position in scPharmaceuticals in the first quarter valued at about $100,000. Thomasville National Bank boosted its stake in shares of scPharmaceuticals by 11.5% during the first quarter. Thomasville National Bank now owns 36,800 shares of the company's stock valued at $185,000 after purchasing an additional 3,800 shares in the last quarter. Finally, Balanced Rock Investment Advisors LLC grew its holdings in shares of scPharmaceuticals by 9.2% during the first quarter. Balanced Rock Investment Advisors LLC now owns 57,248 shares of the company's stock worth $287,000 after purchasing an additional 4,827 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.